Zydus Lifesciences Limited
NSE: ZYDUSLIFE BSE: ZYDUSLIFE
NSE
1,001.25
-12.60 (-1.24%)
Prev Close
1013.85
Open Price
1015.9
Volume
382,044
Today Low / High
997.35 / 1017.15
52 WK Low / High
795 / 1059.05
Range
951 - 1,051
BSE
1,001.35
-12.50 (-1.23%)
Prev Close
1013.85
Open Price
1010.75
Volume
14,809
Today Low / High
997.5 / 1017.05
52 WK Low / High
797.05 / 1059
Range
951 - 1,051
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1001.25 (target range: 951 - 1,051), reflecting a change of -12.6 (-1.24279%). On the BSE, it is listed at 1001.35 (target range: 951 - 1,051), showing a change of -12.5 (-1.23292%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
28 Oct
1,015.90
-1.44%
27 Oct
1,013.55
0.03%
24 Oct
1,008.95
-0.40%
23 Oct
1,013.95
-0.49%
21 Oct
1,002.35
-0.28%
20 Oct
988.00
1.45%
17 Oct
984.00
0.37%
16 Oct
977.30
0.75%
15 Oct
979.25
-0.20%
14 Oct
995.00
-1.58%
13 Oct
990.00
0.56%
10 Oct
997.90
-0.45%
09 Oct
993.00
0.15%
08 Oct
987.90
-0.20%
07 Oct
1,002.00
-1.41%
06 Oct
988.30
0.64%
03 Oct
996.00
-0.77%
01 Oct
981.00
1.03%
30 Sep
995.00
-1.32%
Zydus Lifesciences Limited Graph
Zydus Lifesciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Zydus Lifesciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,001.25, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,001.35 | 1,011.36 | 910.23 - 1,112.50 |
| 1,021.38 | 817.10 - 1,225.65 | ||
| 1,031.39 | 721.97 - 1,340.81 | ||
| Bearish Scenario | 1,001.35 | 991.34 | 892.20 - 1,090.47 |
| 981.32 | 785.06 - 1,177.59 | ||
| 971.31 | 679.92 - 1,262.70 |
Overview of Zydus Lifesciences Limited
ISIN
INE010B01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
958,363
Market Cap
1,007,487,347,951
Last Dividend
11
Official Website
IPO Date
2002-07-01
DCF Diff
-1,846.93
DCF
2,846
Financial Ratios Every Investor Needs
Stock Dividend of ZYDUSLIFE
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-25 | July 25, 25 | 11 | 11 | 2025-07-25 | 2025-08-14 | |
| 2024-07-26 | July 26, 24 | 3 | 3 | 2024-07-26 | 2024-09-08 | |
| 2023-07-27 | July 27, 23 | 6 | 6 | 2023-07-28 | 2023-09-10 | |
| 2022-07-28 | July 28, 22 | 2.5 | 2.5 | 2022-07-29 | 2022-08-16 | |
| 2021-07-28 | July 28, 21 | 3.5 | 3.5 | 2021-07-29 | 2021-09-10 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 23,241.50 Cr | 6,538.40 Cr | 16,703.10 Cr | 0.7187 | 1,944.90 Cr | 3,711.80 Cr | 9,603.70 Cr | 4,525.50 Cr | 44.97 | 6,830.30 Cr | 0.1947 |
| 2024-03-31 | 19,547.40 Cr | 6,393.70 Cr | 13,153.70 Cr | 0.6729 | 1,312.50 Cr | 3,164.00 Cr | 7,595.50 Cr | 3,859.50 Cr | 37.91 | 5,257.20 Cr | 0.1974 |
| 2023-03-31 | 17,237.40 Cr | 6,470.70 Cr | 10,766.70 Cr | 0.6246 | 1,240.80 Cr | 2,788.60 Cr | 5,761.00 Cr | 1,960.30 Cr | 19.35 | 3,534.40 Cr | 0.1137 |
| 2022-03-31 | 15,109.90 Cr | 5,685.70 Cr | 9,424.20 Cr | 0.6237 | 1,045.50 Cr | 2,457.30 Cr | 5,128.90 Cr | 4,487.30 Cr | 21.90 | 3,169.50 Cr | 0.2970 |
| 2021-03-31 | 14,403.50 Cr | 4,943.40 Cr | 9,460.10 Cr | 0.6568 | 1,124.80 Cr | 2,317.90 Cr | 5,210.30 Cr | 2,133.60 Cr | 21.51 | 3,415.20 Cr | 0.1481 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 826.80 Cr | 37,201.70 Cr | 10,843.30 Cr | 23,953.1000 Cr | 3,213.20 Cr | 256.40 Cr | 3,944.00 Cr | 7,359.90 Cr | 72.90 Cr | 0.90 Cr | 1,556.70 Cr | 9,041.6000 Cr |
| 2024-03-31 | 413.00 Cr | 29,280.80 Cr | 7,179.20 Cr | 19,829.5000 Cr | 804.20 Cr | 391.20 Cr | 3,441.90 Cr | 6,914.80 Cr | 0.00 Cr | 1.80 Cr | 11.20 Cr | 5,341.9000 Cr |
| 2023-03-31 | 487.80 Cr | 25,756.40 Cr | 6,068.10 Cr | 17,515.8000 Cr | 1,194.90 Cr | 707.10 Cr | 3,413.30 Cr | 6,826.70 Cr | 1,960.10 Cr | 29.50 Cr | 1,362.60 Cr | 5,530.7000 Cr |
| 2022-03-31 | 657.80 Cr | 27,795.40 Cr | 8,741.60 Cr | 16,999.6000 Cr | 4,220.90 Cr | 3,563.10 Cr | 3,719.40 Cr | 6,422.60 Cr | 1,824.40 Cr | 28.70 Cr | 1,140.10 Cr | 7,839.4000 Cr |
| 2021-03-31 | 665.20 Cr | 23,884.70 Cr | 8,955.10 Cr | 12,992.3000 Cr | 4,607.60 Cr | 3,942.40 Cr | 3,236.20 Cr | 6,333.20 Cr | 1,648.30 Cr | 22.70 Cr | 224.70 Cr | 7,861.3000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 6,776.7000 Cr | -8,372.3000 Cr | 2,014.2000 Cr | 5,064.1000 Cr | 413.8000 Cr | 826.8000 Cr | -1,712.6000 Cr | 4,525.5000 Cr | 2,402.0000 Cr | -302.5000 Cr | -444.9000 Cr |
| 2024-03-31 | 3,196.3000 Cr | -1,475.2000 Cr | -1,778.8000 Cr | 2,321.3000 Cr | -74.8000 Cr | 413.0000 Cr | -906.6000 Cr | 3,859.5000 Cr | -392.9000 Cr | -621.0000 Cr | -2.0000 Cr |
| 2023-03-31 | 2,688.8000 Cr | 1,171.2000 Cr | -4,400.4000 Cr | 1,657.9000 Cr | -533.8000 Cr | 573.1000 Cr | -1,030.9000 Cr | 2,582.7000 Cr | -3,147.2000 Cr | -267.1000 Cr | 440.7000 Cr |
| 2022-03-31 | 2,104.1000 Cr | -1,000.3000 Cr | -868.3000 Cr | 901.5000 Cr | 218.6000 Cr | 3,460.1000 Cr | -1,202.6000 Cr | 5,232.3000 Cr | -383.7000 Cr | -372.2000 Cr | -525.5000 Cr |
| 2021-03-31 | 3,293.0000 Cr | -722.5000 Cr | -2,548.9000 Cr | 2,439.0000 Cr | -90.5000 Cr | 1,087.2000 Cr | -854.0000 Cr | 2,284.8000 Cr | -3,342.7000 Cr | -1.5000 Cr | -479.7000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 6,573.70 Cr | 1,789.50 Cr | 4,784.20 Cr | 0.7278 | 3,779.00 Cr | 1,466.80 Cr | 14.58 | 2,010.83 Cr | 0.2231 |
| 2025-03-31 | 6,527.90 Cr | 1,897.50 Cr | 4,630.40 Cr | 0.7093 | 240.20 Cr | 1,170.90 Cr | 11.64 | 2,125.43 Cr | 0.1794 |
| 2024-12-31 | 5,269.10 Cr | 1,583.40 Cr | 3,685.70 Cr | 0.6995 | 2,739.20 Cr | 1,023.50 Cr | 10.17 | 1,155.50 Cr | 0.1942 |
| 2024-09-30 | 5,237.00 Cr | 1,471.40 Cr | 3,765.60 Cr | 0.7190 | 2,886.40 Cr | 911.20 Cr | 9.06 | 1,406.85 Cr | 0.1740 |
| 2024-06-30 | 6,207.50 Cr | 1,586.10 Cr | 4,621.40 Cr | 0.7445 | 3,737.90 Cr | 1,419.90 Cr | 14.11 | 2,073.40 Cr | 0.2287 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 5,637.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -26,358.40 Cr |
| 2025-03-31 | 826.80 Cr | 7,001.40 Cr | 7,807.90 Cr | 4,024.70 Cr | 3,944.00 Cr | 17,046.10 Cr | 7,359.90 Cr | 37,201.70 Cr | 10,843.30 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 2,495.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -24,154.60 Cr |
| 2024-09-30 | 1,593.60 Cr | 901.40 Cr | 2,495.00 Cr | 4,671.00 Cr | 3,716.90 Cr | 12,156.90 Cr | 7,153.10 Cr | 31,445.90 Cr | 7,291.30 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 1,357.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -22,101.60 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 1,466.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 1,170.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 1,023.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 911.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 1,419.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2015-10-06 | October 06, 15 | 5:1 |
| 2010-04-05 | April 05, 10 | 3:2 |
| 2006-08-30 | August 30, 06 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,687.00 | ₹4,047,671,982,389.00 | ₹2,440,907.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,438.50 | ₹1,709,224,809,162.00 | ₹305,872.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,576.50 | ₹1,210,448,542,500.00 | ₹133,893.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,289.40 | ₹1,073,250,238,305.00 | ₹1,828,269.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹1,001.25 | ₹1,007,487,347,951.00 | ₹382,044.00 |
| Mankind Pharma Limited | MANKIND | ₹2,406.50 | ₹993,303,306,185.00 | ₹271,023.00 |
| Lupin Limited | LUPIN | ₹1,918.70 | ₹876,381,321,332.00 | ₹668,996.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,432.00 | ₹649,477,080,000.00 | ₹156,752.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,099.40 | ₹638,533,304,326.00 | ₹1,130,406.00 |
| Laurus Labs Limited | LAURUSLABS | ₹959.65 | ₹518,042,964,325.00 | ₹2,714,923.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,815.10 | ₹512,222,688,416.00 | ₹339,123.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹859.70 | ₹328,892,970,258.00 | ₹338,239.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,285.90 | ₹326,238,253,926.00 | ₹63,010.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,388.40 | ₹298,396,244,362.00 | ₹56,805.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,686.00 | ₹264,021,258,954.00 | ₹36,351.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,326.00 | ₹251,362,987,122.00 | ₹89,776.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,315.50 | ₹232,887,500,000.00 | ₹17,491.00 |
| Eris Lifesciences Limited | ERIS | ₹1,628.40 | ₹221,810,151,334.00 | ₹201,101.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,296.90 | ₹210,726,538,417.00 | ₹240,869.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹15,740.00 | ₹201,942,452,860.00 | ₹26,058.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹905.60 | ₹178,007,565,094.00 | ₹64,648.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,122.00 | ₹177,893,979,648.00 | ₹220,240.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,012.00 | ₹152,935,532,352.00 | ₹30,388.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹826.50 | ₹148,034,307,555.00 | ₹240,008.00 |
| Granules India Limited | GRANULES | ₹569.95 | ₹138,309,034,684.00 | ₹457,943.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹905.95 | ₹111,143,167,221.00 | ₹89,266.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,183.00 | ₹102,633,978,906.00 | ₹5,459.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹843.00 | ₹76,403,592,867.00 | ₹103,602.00 |
| Strides Pharma Science Limited | STAR | ₹814.00 | ₹75,028,589,196.00 | ₹168,130.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹361.10 | ₹70,624,593,758.00 | ₹144,078.00 |
| FDC Limited | FDC | ₹432.05 | ₹70,342,096,792.00 | ₹151,149.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹457.20 | ₹69,998,260,918.00 | ₹100,352.00 |
| Sequent Scientific Limited | SEQUENT | ₹206.17 | ₹51,524,532,078.00 | ₹1,087,872.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹460.00 | ₹50,124,021,900.00 | ₹1,023,719.00 |
| Innova Captab Limited | INNOVACAP | ₹809.85 | ₹46,343,608,751.00 | ₹13,089.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹142.23 | ₹46,156,705,461.00 | ₹7,842,918.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹481.10 | ₹43,909,997,000.00 | ₹215,251.00 |
| Suven Life Sciences Limited | SUVEN | ₹194.00 | ₹42,299,895,218.00 | ₹85,389.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,377.50 | ₹39,321,508,163.00 | ₹8,656.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹703.85 | ₹35,698,642,054.00 | ₹75,131.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹337.35 | ₹33,830,303,399.00 | ₹45,042.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹465.55 | ₹32,777,396,913.00 | ₹10,150.00 |
Key Executives
Company Secretary & Compliance Officer
Mr. Dhaval Narendra Soni
Gender: male
Year Born:
Chief Financial Officer
Mr. Nitinkumar Dalsukhray Parekh
Gender: male
Year Born:
Chief Operating Officer & Executive Director
Dr. Ganesh Narayan Nayak
Gender: Not Specified
Year Born: 1955
President & Chief Executive Officer of America
Mr. Punit Patel
Gender: male
Year Born:
Head of Investor Relations
Mr. Arvind Bothra
Gender: male
Year Born:
President of Parenteral Operations
Mr. Vikram Shukla
Gender: male
Year Born: 1974
President of Finance
Mr. Tushar Dhansukh Shroff
Gender: male
Year Born:
MD & Executive Director
Dr. Sharvil Pankajbhai Patel
Gender: Not Specified
Year Born: 1979
FAQs about Zydus Lifesciences Limited
Who is the CEO of the company?
The CEO is Punit Patel.
What is the current market price of the stock?
The current price is ₹1,001.25.
What is the 52-week price range?
The range is ₹795-1059.05.
What is the market capitalization of the company?
The market capitalization is ₹100,748.73 crores.
What is the dividend yield?
The dividend yield is 1.10%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 22.03.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Zydus Lifesciences Limited (ISIN: INE010B01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹100,748.73 crores and an average daily volume of 958,363 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹11.